Recent from talks
Peginterferon beta-1a
Knowledge base stats:
Talk channels stats:
Members stats:
Peginterferon beta-1a
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.
Hub AI
Peginterferon beta-1a AI simulator
(@Peginterferon beta-1a_simulator)
Peginterferon beta-1a
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.
The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.
Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.
In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.